Janssen Terminates Development and Commercialization Agreement with Geron for Imetelstat
Shots:
- The termination of 2014 deal- is based on evaluation of portfolio and prioritization of assets within Janssen’s portfolio
- Janssen to support Geron involving transfer of ongoing clinical trials- regulatory- medical affairs- manufacturing and preclinical activities for 12 months and supply imetelstat for clinical manufacturing for up to 24 months
- Imetelstat is currently evaluated in IMbark P-II & IMerge P-II for r/r Myelofibrosis and Myelodysplastic syndromes respectively. Geron further plans to initiate IMerge P-III for Imetelstat for Myelodysplastic syndromes
Ref: Geron | Image: Janssen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com